Similarly, the TGF-β1 activation of colon cancer was greatly reduced when treated with αvβ8 antibodies or β8-siRNA, which indicated that integrin αvβ8 was a mediator of latent TGF-β1 activation for colon cancer. This evidence concerns the gene TGFB1 and malignant colon neoplasm.